Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.
New research from UHN's Peter Munk Cardiac Centre (PMCC) shows statins, commonly prescribed to lower cholesterol and reduce the risk of heart disease and stroke, may also protect the heart from damaging side-effects of early breast cancer treatment.
Cancer chemotherapy changes the function of cells that repair heart injury, researchers at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) discovered.
Scientists have identified a gene which if present in certain breast cancer patients indicates how they will respond to specific therapies.
Scientists have identified a collection of biomarkers that together signal that a person's cancer treatment may be harming their heart.
Many cancers can be successfully treated, but treatment itself often comes with risks as well. Cancer therapy that uses anthracyclines--a class of commonly used chemotherapy drugs--has been associated with heart damage that can eventually result in heart failure. It is thought to be the reason why heart disease is a leading cause of death in cancer survivors, immediately following cancer recurrence.
Statins are widely used to lower cholesterol and prevent heart disease and related deaths, but can they also help guard against heart damage caused by certain breast cancer therapies?
Anthracyclines remain a cornerstone of breast cancer therapy in combination with new-generation targeted drugs such as trastuzumab. Both types of drugs are major culprits in chemotherapy-induced heart disease.
Patients with acute lymphoblastic leukemia or acute myeloid leukemia who are treated with anthracyclines are at a heightened risk of heart failure- most often within one year of exposure to the chemotherapy treatment, according to a new study led by researchers at Penn Medicine.
A new study by Yale Cancer Center researchers shows understanding treatment patterns for patients with acute myeloid leukemia is vital to develop strategies to improve outcomes.
Cancer patients receiving common heart drugs have less heart damage from cancer therapy, according to research presented today at EuroEcho 2019, a scientific congress of the European Society of Cardiology.
A pacemaker-like device restored heart function in a group of cancer survivors -- mostly women with breast cancer -- who had suffered from heart failure as a result of chemotherapy treatment, a study in the Journal of the American Medical Association reports.
A recent large German study has shown that a new combination therapy for breast cancer treatment leads to a lowered risk of the disease coming back. A commentary on this landmark clinical trial has been published in the latest issue of the Journal of Clinical Oncology by the researchers Masey Ross and Charles Geyer Jr. from the VCU Massey Cancer Center. The commentary was titled, “Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?”
Survivors of childhood cancer have a higher risk of developing a range of heart disease due to cancer therapy, according to new research published in the American Heart Association's journal Circulation.
Cheryl Krafft was diagnosed with an aggressive form of non-Hodgkin's lymphoma and was put on a very high-powered chemotherapy regimen to rid her body of the cancer. What she was not counting on was the chemotherapy causing another equally deadly problem.
An imaging procedure commonly performed before starting cancer treatment can provide valuable clues about a patient's risk for heart problems in the months and years after treatment.
Every year, 4 million new cases of cancer are diagnosed in Europe. Advances in cancer treatment sometimes come at the cost of major adverse effects, and one of the most prominent is cardiotoxicity. Myocardial toxicity affects as many as 25% of patients undergoing treatment with commonly used anticancer drugs.
In long-term survivors of childhood cancer, cardiovascular disease is a leading cause of early death from non-cancer causes.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.
For the third time since 2013, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment the added benefit of the drug pertuzumab in the treatment of HER2-positive breast cancer.
Approximately 10-20 percent of diagnosed breast cancers are found to be triple-negative, meaning the breast cancer cells test negative for estrogen and progesterone receptors as well as HER2 receptors, genes that can play a role in the development of breast cancer.